A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Inclusion Criteria:
Main Exclusion Criteria:
Any previous treatment for neovascular AMD.
Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
Ciudad Autonoma de Buenos Aire, C1023AAQ, Argentina
Ciudad Autonoma de Buenos Aire, C1061AAE, Argentina
Ciudad Autonoma de Buenos Aire, C1116ABA, Argentina
North York, Ontario M3C 0GP, Canada
Bogotá, Cundinamarca 110121, Colombia
Praha 4-Krc, 140 59, Czechia
Hyderabad, Andhra Pradesh 500034, India